IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Trial Profile

IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Aldesleukin; Cisplatin; Interferon alpha-2b; Temozolomide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2017 Status changed from completed to discontinued because of Slow accrual & so closed in Phase I.
    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 25 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top